	01702			Sheet 1 of 7
FORM PTO-1449 (Rev. 2-32)	APR 2 4 2002 =	U.S. Department of Commerce Patent and Trademark Offic	Atty. Docket No.	Serial No.
(1464, 2-52)	INFORMATION CLUSE STATEMENT BY APPL	OSURE	99-274-F	10/037,182
	(20000000000000000000000000000000000000		Applicant:	
			Karl Tryggvason, et al.	
			Filing Date:	Group:
			December 21, 2001	IBA 1453

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Dat if Appropriat

FOREIGN PATENT DOCUMENTS

**************************************		Document Number	Date	Country	Class	Subclass	Translatio
rice	1.	WO 00/66730	Nov. 9, 2000				
xcc	2.	WO 00/66731	Nov. 9, 2000		1		
Rec	3.	WO 00/66732	Nov. 9, 2000				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

yes	4.	Altschul, et al., (1990), J. Mol. Biol., 215:403-410.
	5.	Altschul, et al., (1997), Nucleic Acids. Res., 25:3389-3402.
	6.	Aumailley and Kreig, (1996), J. Invest. Dermatology, 106:209-214.
	7.	Aumailley, et al., (1996), In The Laminins, Timpl and Ekblom, eds. Harwood Academic Publishers, Amsterdam, 127-158.
	8.	Aumailley, M., and Smyth, N., (1998), <i>J. Anat.</i> , 193(Pt 1): 1-21.
	9.	Champliaud, MF, et al., (2000), Experiment Cell Research, 259(2): 326-35.
pac	10.	Church, HJ, et al., (1998), Biochemical Journal, 332(2): 491-8.

EXAMINER	K CCarlson	DATE CONSIDERED 5-19-09
	/ 	

FORM PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
(Rev. 2-32)	Patent and Trademark Office	99-274-F	10/037,182
	INFORMATION DISCLOSURE		
	STATEMENT BY APPLICANT		i i
	(Use several sheets if necessary)		
	OIPE	Applicant:	
	Conn.	Karl Tryggvason, et al	
	APR 2 4 2002	Filing Date:	Group:
	CREAT & TRADEMARKS	December 21, 2001	ТВА

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

yec.	11.	Clark, E. A. et al., (1995), <i>Science</i> , 268(5208): 233-9.
	12.	Cleland, et al., (1993), Crit. Rev. Therapeutic Drug Carrier Systems, 10:307-377.
	13.	Colognato, J., (1999), J. Cell Biol., 145:619-631.
	14.	Davis, G. E., et al., (1995), <i>Exp. Cell Res.</i> , 216(1): 113-23.
	15.	De Arcangelis, A., et al., (2001), International Journal of Cancer, 94(1): 44-53.
	16.	Dejana, E., et al., (1993), <i>Kidney Int.</i> , 43(1): 61-5.
	17.	Dixit, P., et al., (2001), <i>J. Biomed. Mater. Res.</i> , 56(4): 545-55.
kce	18.	Durkin, ME, (1997), FEBS Letters, 411(2-3): 296-300.
	19.	Durkin, ME, "Homo sapiens laminin, alpha 5 (LAMA5), MRNA, "Accession No. NM005560, May 30, 2001
	20.	Eble, JA, (1998), <i>Biochemistry</i> , 37(31): 10945-55.
	21.	Ekblom, M., Falk, M., (1998), Annals of the New York Academy of Sciences, 857:194-211.
	22.	El Nemer, W., et al., (2001), Journal of Biological Chemistry, 276(26): 23757-62.
	23.	Engel, J., (1994), Methods <i>Enzymol.</i> , 245:469-88.
	24.	Faury, Ristori, G., et al., (1995), Journal of Vascular Research, 32(2): 112-9.
	25.	Ferletta, M. et al., (1999), <i>J. Cell Sci.</i> , 112(Pt. 1): 1-10.
	26.	Frojdman, K., et al., (1999), <i>Differentiation</i> , 64(3): 151-9.
	27.	Fujiwara, H., et al., (2001), <i>J. Biol. Chem.</i> , 276(20): 17550-8.
	28.	Geberhiwot, T., et al., (2001), Journal of Cell Science, 114(Pt. 2): 423-33.
pre	29.	Goodwin, AE, et al., (1995), Journal of Immunological Methods, 187(2): 213-9.

EXAMINER CCarbon	DATE CONSIDERED 5-19-04
------------------	-------------------------

	Sheet 3 of 7	
Atty. Dock t No.	Serial No.	
99-274-F	10/037,182	

Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT

FORM PTO-1449

(Rev. 2-32)

(Use several sheets if necessary)

Applicant:

Karl Tryggvason, et al.

Filing Date:

Group:

December 21, 2001

TBA

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

U.S. D partment of Commerce

_

	EXAMINER MCCarlen	DATE CONSIDERED 3-19-04
--	-------------------	-------------------------

Sheet 4 of 7

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
(Nev. 2-52)	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	99-274-F	10/037,182
	(Use several sheets if necessary)		
	OTPE	Applicant:	
	2000 =	Karl Tryggvason, et al.	
	APR 2 4 2002	Filing Date:	Group:
	FEBRE TRADEMARKO	December 21, 2001	TBA

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

yec.	49.	Ling, A. Dai, et al., (1999), <i>Hypertension</i> , 34(5): 1141-6.
	50.	Lin, L., et al., (2000), Experimental Eye Research, 70(4): 537-46.
	51.	Ljubimov AV, et al., (1998), Journal of Histochemistry & Cytochemistry, 46(9): 1033-41.
	52.	Madri, J.A., et al., (1988), Am. J. Pathol., 132(1):18-27.
	53. Madri, J.A., et al., (1991), <i>J. Cell Biochem.</i> , 45(2):123-30.	
	54.	Malinda and Kleinman, (1996), Cell Biol., Int. J. Biochem, 28:957-959.
yei	55.	Miner, J.H., et al., (1995), J. Biol. Chem., 270(48): 28523-6.
pe	56.	Miner, J.H., et al., (1997), J. Cell Biol., 137(3): 685-701.
	57.	Miner, J.H. et al., "Mus Musculus laminin alpha 5 chain (Lama5) MRNA, partial cds.," Acession No. U37501, November 10, 1997.
	58.	Miner, J.H., et al., (1998), J. Cell Biol., 143(6): 1713-23.
	59.	Miner, J.H., et al., (2000), <i>Dev. Biol.</i> , 217(2): 278-89.
-	60. Nielsen, P.K., et al., (2000), Journal of Biological Chemistry, 275(19): 14517-23.	
61. Nielsen, P.K., et al., (2001), J. Biol. Chem., 276(14): 10906-12.		Nielsen, P.K., et al., (2001), J. Biol. Chem., 276(14): 10906-12.
62. Parsons, SF, et al., (2001), Blood, 97(1): 312-20.		Parsons, SF, et al., (2001), <i>Blood</i> , 97(1): 312-20.
63. Patton, B. L., et al., (1997), J. Cell Biol., 139(6): 1507-21.		Patton, B. L., et al., (1997), J. Cell Biol., 139(6): 1507-21.
	64. Pedraza, C. Geberhiwot, (2000), Journal of Immunology, 165(10): 5831-8.	
	65. Pevec, W. C., et al., (1992), J. Vasc. Surg., 16(1): 60-5.	
	66.	Pierschbacher, M.D., et al., (1984), <i>Nature</i> , 309(5963): 30-3.
Vee	67.	Pikkarainen, T., et al., (1992), <i>Eur. J. Biochem.</i> , 209(2):571-82.

EXAMINER, CCarpon	DATE CONSIDERED
// Clarpur	5-17-09

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Dock t No. 99-274-F	Serial No. 10/037,182
	Use several sheets if necessary)		
	OIPE	Applicant:	
		Karl Tryggvason, et al.	
	APR 2 4 2002	Filing Date:	Group:
	TELL MATOR	December 21, 2001	TBA

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

jer.	68.	Pinckard, et al., (1967), Clin. Exp. Immunol., 2:331-340.
	69.	Pouliot, N., et al., (2000), Experimental Cell Research, 261(2): 360-71.
70. Pouliot, N., et al., (2001), Exp. Cell Res., 266(1), 1-10.		Pouliot, N., et al., (2001), Exp. Cell Res., 266(1), 1-10.
	71. Robbins, et al., (1987), <i>Diabetes</i> , 36:838-845.	
72. Sanes, JR., et al., (1998), Journal of Physiology, 92(3-4): 167-72.		Sanes, JR., et al., (1998), Journal of Physiology, 92(3-4): 167-72.
	73.	Seebacher, T., et al., (1997), Experimental Cell Research, 237(1): 70-6.
	74.	Shah, BH, et al., (1992), <i>Brain Research</i> , 589(2): 268-74.
	75.	Shattil, S.J., et al., (1997), <i>J. Clin. Invest.</i> , 100(11 Suppl), S91-5.
	76.	Siler, U., Seiffert M., (2000), <i>Blood</i> , 96(13): 4194-203.
	77.	Sixt, M., (2001), Journal of Cell Biology, 153(5): 933-46.
	78.	Sixt, M., et al., (2001), J. Biol. Chem., 276(22), 18878-87.
	79. Skelton, HG, (1998), American Journal of Dermatopathology, 20(6): 547-50.	
	80.	Sorokin, L. M., et al., (1997), <i>Dev. Biol.</i> , 189(2): 285-300.
	81.	Sorokin, L. M., et al., (1997), Dev. Dyn., 210(4):446-62.
	82.	Sorokin, L., et al., (1994), Eur. J. Biochem., 223(2):603-10.
	83.	Spessotto, P. Yin, et al., (2001), Cancer Research, 61(1): 339-47.
	84.	Tani, T., et al., (1999), Exp. Cell Res., 248(1): 115-21.
	85.	Timpl, R., and Brown, J.C., (1994), <i>Matrix Biol.</i> , 14(4): 275-281.
ice	86.	Tokida, Y., et al., (1990), J. Biol. Chem., 265(30): 18123-9.

EXAMINER	& CCarlson	DATE CONSIDERED 5-19-04

			Sheet 6 of 7
FORM PTO-1449	U.S. Department of Commerce	Atty. Docket No.	Serial No.
(Rev. 2-32)	Patent and Trademark Office	99-274-F	10/037,182
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
	(Use several sheets if necessary)		
	OIPE	Applicant:	
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Karl Tryggvason, et al.	
	APR 2 4 2002 =	Filing Date:	Group:
	TRANSMIN OF	December 21, 2001	ТВА

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

Vec 87. Vanderboom, RJ, et al., (1989), Journal of Reproduction & Fertility, 87(1): 81-7.		Vanderboom, RJ, et al., (1989), Journal of Reproduction & Fertility, 87(1): 81-7.	
	88.	Varani, J., et al., (1995), Journal of Biomedical Materials Research, 29(8): 993-7.	
	89.	Virtanen, I., et al., (1997), Am. J. Pathol., 150(4):1421-31.	
	90. Wang, YG, Samarel, et al., (2000), Journal of Physiology, 526(Pt. 1): 57-68.		
	91.	Watelet, J., et al., (1997), Ann. Vasc. Surg., 11(5): 510-9.	
	92.	Wayner, E.A., et al., (1993), <i>J. Cell Biol.</i> , 121(5): 1141-52.	
	93.	Wewer and Engvall, (1996), Neuromusc. Disord., 6:409-418.	
	94.	Woerly, S., et al., (1996), Neuroscience Letters, 205(3) 197-201.	
ree	95.	Yurchenco, et al., (1997), <i>Proc. Natl. Acad. Sci.</i> , 94:10189-10194.	

EXAMINER 1/00 /	DATE CONSIDERED - 15-01/
Massar.	3 = 11 = 09